2,388
Views
6
CrossRef citations to date
0
Altmetric
Articles

Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism with or without previous parathyroidectomy: a retrospective study

, , ORCID Icon, , , , , , , & show all
Pages 907-917 | Received 13 Apr 2022, Accepted 28 Jun 2022, Published online: 17 Jul 2022

References

  • Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145–158.
  • Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(11):3993–4004.
  • Kidney Disease: Improving Global Outcomes, C.K.D.M.B.D.U.W.G. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and bone disorder (CKD-MBD). 2017. Kidney Int Suppl. 2011;7(1):1–59.
  • Cozzolino M, Galassi A, Conte F, et al. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Ther Clin Risk Manag. 2017;13:679–689.
  • Henry JF. Reoperation for primary hyperparathyroidism: tips and tricks. Langenbecks Arch Surg. 2010;395(2):103–109.
  • Stracke S, Keller F, Steinbach G, et al. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. 2009;111(2):c102–9.
  • Zitt E, Rix M, Ureña Torres P, et al. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study. Nephrol Dial Transplant. 2011;26(6):1956–1961.
  • Liu F, Yu X, Liu Z, et al. Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism. Int J Hyperthermia. 2019;36(1):835–840.
  • Liu C, Wu B, Huang P, et al. US-Guided percutaneous microwave ablation for primary hyperparathyroidism with parathyroid nodules: Feasibility and safety study. J Vasc Interv Radiol. 2016;27(6):867–875.
  • Fan B-Q, He X-W, Chen H-H, et al. US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study. Eur Radiol. 2019;29(10):5607–5616.
  • Xu S-y, Wang Y, Xie Q, et al. Percutaneous sonography-guided radiofrequency ablation in the management of parathyroid adenoma. Singapore Med J. 2013;54(7):e137-40–e140.
  • Kim BS, Eom TI, Kang KH, et al. Radiofrequency ablation of parathyroid adenoma in primary hyperparathyroidism. J Med Ultrason (2001). 2014;41(2):239–243.
  • Sormaz IC, Poyanlı A, Açar S, et al. The results of ultrasonography-guided percutaneous radiofrequency ablation in hyperparathyroid patients in whom surgery is not feasible. Cardiovasc Intervent Radiol. 2017;40(4):596–602.
  • Korkusuz H, Wolf T, Grunwald F. Feasibility of bipolar radiofrequency ablation in patients with parathyroid adenoma: a first evaluation. Int J Hyperthermia. 2018;34(5):639–643.
  • Sung JY, Baek JH, Kim KS, et al. Symptomatic nonfunctioning parathyroid cysts: role of simple aspiration and ethanol ablation. Eur J Radiol. 2013;82(2):316–320.
  • Lin W-C, Kan N-N, Chen H-L, et al. Efficacy and safety of single-session radiofrequency ablation for benign thyroid nodules of different sizes: a retrospective study. Int J Hyperthermia. 2020;37(1):1082–1089.
  • Figari M, Musso CG, Plantalech L, et al. Local ethanol injection for the treatment of deltoid parathyroid cell hyperplasia. Int Urol Nephrol. 2014;46(1):247–249.
  • Onoda N, Kurihara S, Sakurai Y, et al. A case of secondary hyperparathyroidism whose high turnover bone improved after the direct injection of acetic acid into the parathyroid glands. Clin Nephrol. 2004;61(1):68–73.
  • Jiang T, Chen F, Zhou X, et al. Percutaneous ultrasound-guided laser ablation with contrast-enhanced ultrasonography for hyperfunctioning parathyroid adenoma: a preliminary case series. Int J endocrinol. 2015. 2015;2015:673604.
  • Bennedbaek FN, Karstrup S, Hegedus L. Ultrasound guided laser ablation of a parathyroid adenoma. Br J Radiol. 2001;74(886):905–907.
  • Andrioli M, Riganti F, Pacella CM, et al. Long-term effectiveness of ultrasound-guided laser ablation of hyperfunctioning parathyroid adenomas: present and future perspectives. AJR Am J Roentgenol. 2012;199(5):1164–1168.
  • Kovatcheva RD, Vlahov JD, Stoinov JI, et al. High-intensity focussed ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27(1):76–80.
  • Kovatcheva R, Vlahov J, Stoinov J, et al. US-guided high-intensity focused ultrasound as a promising non-invasive method for treatment of primary hyperparathyroidism. Eur Radiol. 2014;24(9):2052–2058.
  • Zhuo L, Zhang L, Peng LL, et al. Microwave ablation of hyperplastic parathyroid glands is a treatment option for end-stage renal disease patients ineligible for surgical resection. Int J Hyperthermia. 2019;36(1):29–35.
  • Diao Z, Wang L, Li D, et al. Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis. Ren Fail. 2017;39(1):140–145.
  • Zeng Z, Peng CZ, Liu JB, et al. Efficacy of ultrasound-guided radiofrequency ablation of parathyroid hyperplasia: single session vs. two-session for effect on hypocalcemia. Sci Rep. 2020;10(1):6206.
  • Peng C, Zhang Z, Liu J, et al. Efficacy and safety of ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease. Head Neck. 2017;39(3):564–571.
  • Yu MA, Yao L, Zhang L, et al. Safety and efficiency of microwave ablation for recurrent and persistent secondary hyperparathyroidism after parathyroidectomy: a retrospective pilot study. Int J Hyperthermia. 2016;32(2):180–186.
  • Bae JH, Choi HJ, Lee Y, et al. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J Korean Med Sci. 2012;27(8):890–895.
  • Ha EJ, Baek JH, Lee JH. Moving-shot versus fixed electrode techniques for radiofrequency ablation: comparison in an ex-vivo bovine liver tissue model. Korean J Radiol. 2014;15(6):836–843.
  • Sacks D, McClenny TE, Cardella JF, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–S202.
  • Goldfarb M, Gondek SS, Lim SM, et al. Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin. World J Surg. 2012;36(6):1314–1319.
  • Ha EJ, Baek JH, Baek SM. Minimally invasive treatment for benign parathyroid lesions: treatment efficacy and safety based on nodule characteristics. Korean J Radiol. 2020;21(12):1383–1392.
  • Karakas E, Müller H-H, Schlosshauer T, et al. Reoperations for primary hyperparathyroidism–improvement of outcome over two decades. Langenbecks Arch Surg. 2013;398(1):99–106.
  • Nawrot I, Chudziński W, Ciąćka T, et al. Reoperations for persistent or recurrent primary hyperparathyroidism: results of a retrospective cohort study at a tertiary referral center. Med Sci Monit. 2014;20:1604–1612.
  • Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S, et al. Outcomes of parathyroidectomy in patients with primary hyperparathyroidism: a systematic review and meta-analysis. World J Surg. 2016;40(10):2359–2377.
  • Tisell L-E, Jansson S, Nilsson B, et al. Transient rise in intact parathyroid hormone concentration after surgery for primary hyperparathyroidism. Br J Surg. 2005;83(5):665–669.
  • Abugassa S, Nordenström J, Eriksson S, et al. Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. Surgery. 1990;107(2):128–133.
  • Brace C. Thermal tumor ablation in clinical use. IEEE Pulse. 2011;2(5):28–38.
  • Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.